Loading...
Loading...
BNR| Name | Value |
|---|---|
| Revenues | 142.5M |
| Cost of Revenue | 43.7M |
| Gross Profit | 98.8M |
| Operating Expense | 287.2M |
| Operating I/L | -188.5M |
| Other Income/Expense | 3.6M |
| Interest Income | 3.1M |
| Pretax | -184.8M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -185.3M |
Burning Rock Biotech Limited is a leading provider of cancer therapy selection tests in China. The company operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. It offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests for various cancer types using tissue and liquid biopsy samples. Key products include OncoCompass IO, OncoScreen IO, OncoCompass Target, ColonCore, OncoScreen ParpMatch, and OncoCompass ParpMatch. Burning Rock Biotech has strategic collaborations with major pharmaceutical companies and has licensing agreements with industry leaders. Its revenue is generated through the sale of these tests and through partnerships with other biotech and pharmaceutical companies.
